The FDA approved a Phase II trial for ExoFlo to treat patients with COVID-19. EXIT COVID-19 is a multi-center, randomized, double-blinded, placebo-controlled trial that will enroll 60 COVID-19 patients with moderate-to-severe ARDS at three research sites across the U.S. The primary efficacy endpoints will be all-cause mortality and median days to recovery. ExoFlo is derived from bone marrow and have been effective with patients with other medical conditions. This product is possibly the most advanced product in Regenerative Medicine. In addition to patient outcomes, ExoFlo offers more advantages. If this study is successful, researchers will continue into Phase III.